Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RGBP huge cancer news below!!
Regen BioPharma Files Patent Application on New Therapy That Uses the ""Innate"" Immune System to Kill Cancer
Sep 16, 2014 11:43:00 (ET)
Regen BioPharma Files Patent Application on New Therapy That Uses the "Innate" Immune System to Kill Cancer
Invention Leverages Research Discoveries in Development of dCellVax for New Cancer Immunotherapy Product
SAN DIEGO, CA--(Marketwired - Sep 16, 2014) - Regen BioPharma Inc. (OTCBB: RGBP) announced today filing of a patent application covering novel means of stimulating the "innate" immune system to kill cancer. The patent discloses specific siRNA molecules that were discovered by Regen BioPharma during the preclinical development of dCellVax. Preliminary data generated by the Company suggests that the new approach appears effective against various human cancers including lung, skin, glioma, and breast cancer.
The patent application describes the utilization of gene silencing, which is the basis of the Company's dCellVax product, together with specific peptides that have previously been demonstrated to stimulate aspects of the innate immune system that is effective at inducing tumor regression.
"To my knowledge there is only one reproducible system in which cancer is destroyed by the immune system, this is the SR/CR mice developed by Wake Forest University(1) . In these mice, which are resistant to challenges with various tumors, the 'innate' and not the 'adaptive' immune system is responsible for eradication of the cancer," said Thomas Ichim, Ph.D., Chief Scientific Officer of Regen BioPharma. "By following the example of nature and focusing augmenting immune responses that are already known to be effective, we believe we are pioneering a novel approach to treatment of cancer."
The immune system is divided into "innate," which recognizes threats to the body regardless of prior exposures to the threat, and "adaptive," which recognizes threats that the body has previously been exposed to. The majority of cancer immunotherapies in clinical development and FDA trials, including checkpoint inhibitors and CAR-T cells work through the "adaptive" immune system.
"While our efforts are focused on moving forward towards initiation of our HemaXellerate clinical trial and filing the IND for dCellVax, intellectual property on these novel products positions us for the possibility of licensing and co-development deals, which does not detract from the core developmental operations," said David Koos, Ph.D., Chairman & CEO of Regen BioPharma Inc.
The Company is currently preparing to file an IND application on its dCellVax therapy, which involves gene silencing for treating cancer.
About Regen BioPharma Inc.: Regen BioPharma Inc. (OTCBB: RGBP) is a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN). Regen is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials.
Currently the Company is focused on developing treatments for Aplastic Anemia and a gene silencing therapy for treating cancer. For more information refer to the company's website http://www.regenbiopharma.com/
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
References
(1) Hicks AM et al. Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proceedings of the National Academy of Sciences USA, 2006, 103:7753.
Contact:
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
Phone: 619-702-1404
Fax: 619.330.2328
www.regenbiopharma.com
(MORE TO FOLLOW) Dow Jones Newswires
September 16, 2014 11:43 ET (15:43 GMT)
RGBP huge cancer news below!!
Regen BioPharma Files Patent Application on New Therapy That Uses the ""Innate"" Immune System to Kill Cancer
Sep 16, 2014 11:43:00 (ET)
Regen BioPharma Files Patent Application on New Therapy That Uses the "Innate" Immune System to Kill Cancer
Invention Leverages Research Discoveries in Development of dCellVax for New Cancer Immunotherapy Product
SAN DIEGO, CA--(Marketwired - Sep 16, 2014) - Regen BioPharma Inc. (OTCBB: RGBP) announced today filing of a patent application covering novel means of stimulating the "innate" immune system to kill cancer. The patent discloses specific siRNA molecules that were discovered by Regen BioPharma during the preclinical development of dCellVax. Preliminary data generated by the Company suggests that the new approach appears effective against various human cancers including lung, skin, glioma, and breast cancer.
The patent application describes the utilization of gene silencing, which is the basis of the Company's dCellVax product, together with specific peptides that have previously been demonstrated to stimulate aspects of the innate immune system that is effective at inducing tumor regression.
"To my knowledge there is only one reproducible system in which cancer is destroyed by the immune system, this is the SR/CR mice developed by Wake Forest University(1) . In these mice, which are resistant to challenges with various tumors, the 'innate' and not the 'adaptive' immune system is responsible for eradication of the cancer," said Thomas Ichim, Ph.D., Chief Scientific Officer of Regen BioPharma. "By following the example of nature and focusing augmenting immune responses that are already known to be effective, we believe we are pioneering a novel approach to treatment of cancer."
The immune system is divided into "innate," which recognizes threats to the body regardless of prior exposures to the threat, and "adaptive," which recognizes threats that the body has previously been exposed to. The majority of cancer immunotherapies in clinical development and FDA trials, including checkpoint inhibitors and CAR-T cells work through the "adaptive" immune system.
"While our efforts are focused on moving forward towards initiation of our HemaXellerate clinical trial and filing the IND for dCellVax, intellectual property on these novel products positions us for the possibility of licensing and co-development deals, which does not detract from the core developmental operations," said David Koos, Ph.D., Chairman & CEO of Regen BioPharma Inc.
The Company is currently preparing to file an IND application on its dCellVax therapy, which involves gene silencing for treating cancer.
About Regen BioPharma Inc.: Regen BioPharma Inc. (OTCBB: RGBP) is a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN). Regen is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials.
Currently the Company is focused on developing treatments for Aplastic Anemia and a gene silencing therapy for treating cancer. For more information refer to the company's website http://www.regenbiopharma.com/
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
References
(1) Hicks AM et al. Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proceedings of the National Academy of Sciences USA, 2006, 103:7753.
Contact:
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
Phone: 619-702-1404
Fax: 619.330.2328
www.regenbiopharma.com
(MORE TO FOLLOW) Dow Jones Newswires
September 16, 2014 11:43 ET (15:43 GMT)
RGBP huge cancer news below!!
Regen BioPharma Files Patent Application on New Therapy That Uses the ""Innate"" Immune System to Kill Cancer
Sep 16, 2014 11:43:00 (ET)
Regen BioPharma Files Patent Application on New Therapy That Uses the "Innate" Immune System to Kill Cancer
Invention Leverages Research Discoveries in Development of dCellVax for New Cancer Immunotherapy Product
SAN DIEGO, CA--(Marketwired - Sep 16, 2014) - Regen BioPharma Inc. (OTCBB: RGBP) announced today filing of a patent application covering novel means of stimulating the "innate" immune system to kill cancer. The patent discloses specific siRNA molecules that were discovered by Regen BioPharma during the preclinical development of dCellVax. Preliminary data generated by the Company suggests that the new approach appears effective against various human cancers including lung, skin, glioma, and breast cancer.
The patent application describes the utilization of gene silencing, which is the basis of the Company's dCellVax product, together with specific peptides that have previously been demonstrated to stimulate aspects of the innate immune system that is effective at inducing tumor regression.
"To my knowledge there is only one reproducible system in which cancer is destroyed by the immune system, this is the SR/CR mice developed by Wake Forest University(1) . In these mice, which are resistant to challenges with various tumors, the 'innate' and not the 'adaptive' immune system is responsible for eradication of the cancer," said Thomas Ichim, Ph.D., Chief Scientific Officer of Regen BioPharma. "By following the example of nature and focusing augmenting immune responses that are already known to be effective, we believe we are pioneering a novel approach to treatment of cancer."
The immune system is divided into "innate," which recognizes threats to the body regardless of prior exposures to the threat, and "adaptive," which recognizes threats that the body has previously been exposed to. The majority of cancer immunotherapies in clinical development and FDA trials, including checkpoint inhibitors and CAR-T cells work through the "adaptive" immune system.
"While our efforts are focused on moving forward towards initiation of our HemaXellerate clinical trial and filing the IND for dCellVax, intellectual property on these novel products positions us for the possibility of licensing and co-development deals, which does not detract from the core developmental operations," said David Koos, Ph.D., Chairman & CEO of Regen BioPharma Inc.
The Company is currently preparing to file an IND application on its dCellVax therapy, which involves gene silencing for treating cancer.
About Regen BioPharma Inc.: Regen BioPharma Inc. (OTCBB: RGBP) is a majority owned subsidiary of Bio-Matrix Scientific Group, Inc. (PINKSHEETS: BMSN). Regen is a biotechnology company focused on identifying undervalued regenerative medicine applications in the stem cell space and rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials.
Currently the Company is focused on developing treatments for Aplastic Anemia and a gene silencing therapy for treating cancer. For more information refer to the company's website http://www.regenbiopharma.com/
Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
References
(1) Hicks AM et al. Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proceedings of the National Academy of Sciences USA, 2006, 103:7753.
Contact:
Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
Phone: 619-702-1404
Fax: 619.330.2328
www.regenbiopharma.com
(MORE TO FOLLOW) Dow Jones Newswires
September 16, 2014 11:43 ET (15:43 GMT)
AMBS just hit my scanner and huge news!!
AMBS just hit my scanner and huge news!!
HUGE bid support! Next leg up starting here!
VIIC is blowing up today!!
VIIC is blowing up today!!
DJ UBS: Sunesis Could Triple After Study Data -- Market Talk
Aug 27, 2014 13:16:00 (ET)
13:16 EDT - Sunesis (SNSS) is expected to soon announce late-stage study data for its blood-cancer drug, and UBS predicts results will be positive as it contends investors have been "overly cautious" going in to the disclosure. If the study is a home run, SNSS could spike to $25 and even higher afterwards on M&A speculation, the investment bank posits. It adds that in a best-case scenario, the drug could peak at $1.5B of annual sales. But if the study shows the drug works without a huge benefit, peak sales are more like to be $400M. A study failure, meanwhile, could have the stock crash to "near-current cash levels" of 60c/share. SNSS is up 6% at $7.94, hitting a fresh 4 1/2-year high. (joseph.walker@wsj.com)
(END) Dow Jones Newswires
DJ UBS: Sunesis Could Triple After Study Data -- Market Talk
Aug 27, 2014 13:16:00 (ET)
13:16 EDT - Sunesis (SNSS) is expected to soon announce late-stage study data for its blood-cancer drug, and UBS predicts results will be positive as it contends investors have been "overly cautious" going in to the disclosure. If the study is a home run, SNSS could spike to $25 and even higher afterwards on M&A speculation, the investment bank posits. It adds that in a best-case scenario, the drug could peak at $1.5B of annual sales. But if the study shows the drug works without a huge benefit, peak sales are more like to be $400M. A study failure, meanwhile, could have the stock crash to "near-current cash levels" of 60c/share. SNSS is up 6% at $7.94, hitting a fresh 4 1/2-year high. (joseph.walker@wsj.com)
(END) Dow Jones Newswires
DJ UBS: Sunesis Could Triple After Study Data -- Market Talk
Aug 27, 2014 13:16:00 (ET)
13:16 EDT - Sunesis (SNSS) is expected to soon announce late-stage study data for its blood-cancer drug, and UBS predicts results will be positive as it contends investors have been "overly cautious" going in to the disclosure. If the study is a home run, SNSS could spike to $25 and even higher afterwards on M&A speculation, the investment bank posits. It adds that in a best-case scenario, the drug could peak at $1.5B of annual sales. But if the study shows the drug works without a huge benefit, peak sales are more like to be $400M. A study failure, meanwhile, could have the stock crash to "near-current cash levels" of 60c/share. SNSS is up 6% at $7.94, hitting a fresh 4 1/2-year high. (joseph.walker@wsj.com)
(END) Dow Jones Newswires
NICE DIP TO LOAD UP ON!! GREAT EARNING AND THE STOCKS DOWN TODAY! IM DEFINITELY BUYING HERE!
this is my work. i work from home
Why does the stock keep tanking then?
SLTD news below!! Great future ahead!
http://money.cnn.com/news/newsfeeds/articles/marketwire/1138350.htm
SLTD news below!! Great future ahead!
http://money.cnn.com/news/newsfeeds/articles/marketwire/1138350.htm
SLTD news below!! Great future ahead!
http://money.cnn.com/news/newsfeeds/articles/marketwire/1138350.htm
MYEC Below
Their most recent quarterly report covers the quarter ended June 30, and it reports:
cash: $1 million
current assets: $1.6 million
current liabilities: $501.7 thousand
revenue: $182.2 thousand
MYEC PR announced their positive Q2 results, and also informed us of their intention to become fully reporting and audited. Supposedly, the required Form 10 will be filed soon. MYEC also disclosed that during the Q2, it has entered into services agreements with iCard1 and VX Gateway, which in turn lead to an increase in revenue.
MYEC Below
Their most recent quarterly report covers the quarter ended June 30, and it reports:
cash: $1 million
current assets: $1.6 million
current liabilities: $501.7 thousand
revenue: $182.2 thousand
MYEC PR announced their positive Q2 results, and also informed us of their intention to become fully reporting and audited. Supposedly, the required Form 10 will be filed soon. MYEC also disclosed that during the Q2, it has entered into services agreements with iCard1 and VX Gateway, which in turn lead to an increase in revenue.
MYEC Below
Their most recent quarterly report covers the quarter ended June 30, and it reports:
cash: $1 million
current assets: $1.6 million
current liabilities: $501.7 thousand
revenue: $182.2 thousand
MYEC PR announced their positive Q2 results, and also informed us of their intention to become fully reporting and audited. Supposedly, the required Form 10 will be filed soon. MYEC also disclosed that during the Q2, it has entered into services agreements with iCard1 and VX Gateway, which in turn lead to an increase in revenue.
Their most recent quarterly report covers the quarter ended June 30, and it reports:
cash: $1 million
current assets: $1.6 million
current liabilities: $501.7 thousand
revenue: $182.2 thousand
MYEC PR announced their positive Q2 results, and also informed us of their intention to become fully reporting and audited. Supposedly, the required Form 10 will be filed soon. MYEC also disclosed that during the Q2, it has entered into services agreements with iCard1 and VX Gateway, which in turn lead to an increase in revenue.
ACHN is gonna blow up today!
Looks like someone is loading up shares of $INHC
Might be a runner one of these days looks super thin. It moved up 130% on nothing
Date Close/Last Volume
08/08/2014 0.015 0
08/07/2014 0.015 0
08/06/2014 0.015 0
08/05/2014 0.015 11,000
08/04/2014 0.015 200
08/01/2014 0.0095 10,000
07/31/2014 0.01 345,200
07/30/2014 0.004 0
07/29/2014 0.004 2,500
07/28/2014 0.0035 468,171
07/25/2014 0.0023 0
07/24/2014 0.0023 0
07/23/2014 0.0023 25,000
NEW HIGHS COMING 31X32
EMAIL ALERTS WITH TBEV BLOWING UP MY INBOX
EMAIL ALERTS WITH TBEV BLOWING UP MY INBOX
EMAIL ALERTS WITH TBEV BLOWING UP MY INBOX
TBEV UP 50% AND STILL ROCKIN!
TBEV IS BLOWING UP!!
TBEV about to blow up!
$DRL News Below
The Securities Arbitration Law Firm of Klayman & Toskes & Carlo Law Offices File $700,000 Claim Against UBS Financial Service...
The Securities Arbitration Law Firm of Klayman & Toskes, P.A., www.perdidasenbonospr.com; www.sueubspuertorico.com, together with Carlo Law Offices, P.S.C. located in Puerto Rico, announced today that they filed a claim against UBS Financial Services Incorporated of Puerto Rico and UBS Financial Services, Inc. (NYSE: UBS) (collectively “UBS”). According to the Claim, the Claimant, a business owner in Puerto Rico, entrusted assets with UBS with the objective of current income and capital appreciation. However, UBS ended up concentrating his whole account in preferred and common stock closely tied to the performance of Puerto Rico’s economy, including First Bancorp Puerto Rico (NYSE: FBP), Doral Financial Corp. (NYSE: DRL), and W. Holding Co. (Westernbank) (OTC: WHCI). By 2009, just as Claimant was in the midst of diversifying his career to endure a failing economy, UBS failed to diversify his portfolio.
UBS purchased and held for Claimant common and preferred stock from banks in Puerto Rico. The Claimant believed the purchases were consistent with his stated risk tolerance of low to moderate risk. However the over concentration in these bank stocks was fraught with excessive risk given the Claimant’s investment objectives. UBS failed to disclose to Claimant the risks associated with over concentrating the account in these securities, which appeared diversified but in reality depended solely in the performance of Puerto Rico's economy. Had this information and the true nature of the risk of the recommended allocation been known to Claimant or properly disclosed, he would not have invested his assets in these products.
The sole purpose of this release is to investigate, on behalf of our clients, the sales practices of UBS in connection with investment recommendations provided to their customers. Current and former customers of UBS who have information relating the investment advice provided by the firm, are encouraged to contact Steven D. Toskes of Klayman & Toskes, or Lcdo. Osvaldo Carlo of Carlo Law Offices, at (787) 919-7325, or visit us on the web at www.perdidasenbonospr.com or www.sueubspuertorico.com.
$DRL News Below
The Securities Arbitration Law Firm of Klayman & Toskes & Carlo Law Offices File $700,000 Claim Against UBS Financial Service...
The Securities Arbitration Law Firm of Klayman & Toskes, P.A., www.perdidasenbonospr.com; www.sueubspuertorico.com, together with Carlo Law Offices, P.S.C. located in Puerto Rico, announced today that they filed a claim against UBS Financial Services Incorporated of Puerto Rico and UBS Financial Services, Inc. (NYSE: UBS) (collectively “UBS”). According to the Claim, the Claimant, a business owner in Puerto Rico, entrusted assets with UBS with the objective of current income and capital appreciation. However, UBS ended up concentrating his whole account in preferred and common stock closely tied to the performance of Puerto Rico’s economy, including First Bancorp Puerto Rico (NYSE: FBP), Doral Financial Corp. (NYSE: DRL), and W. Holding Co. (Westernbank) (OTC: WHCI). By 2009, just as Claimant was in the midst of diversifying his career to endure a failing economy, UBS failed to diversify his portfolio.
UBS purchased and held for Claimant common and preferred stock from banks in Puerto Rico. The Claimant believed the purchases were consistent with his stated risk tolerance of low to moderate risk. However the over concentration in these bank stocks was fraught with excessive risk given the Claimant’s investment objectives. UBS failed to disclose to Claimant the risks associated with over concentrating the account in these securities, which appeared diversified but in reality depended solely in the performance of Puerto Rico's economy. Had this information and the true nature of the risk of the recommended allocation been known to Claimant or properly disclosed, he would not have invested his assets in these products.
The sole purpose of this release is to investigate, on behalf of our clients, the sales practices of UBS in connection with investment recommendations provided to their customers. Current and former customers of UBS who have information relating the investment advice provided by the firm, are encouraged to contact Steven D. Toskes of Klayman & Toskes, or Lcdo. Osvaldo Carlo of Carlo Law Offices, at (787) 919-7325, or visit us on the web at www.perdidasenbonospr.com or www.sueubspuertorico.com.
Money runners banking on SLTD today!
GRCU CEO AND CHART BELOW
CHECK OUT >>>> http://investorshub.advfn.com/boards/read_msg.aspx?message_id=104602854
Robert Calkin, Chief Executive Officer
Robert Calkin has over 25 years of experience in the cannabis industry. Mr. Calkin has helped create numerous marijuana businesses that are successful today. He is a delivery service expert and is sought after for training throughout the cannabis industry. He created Green Dot Delivery Service in Los Angeles in 1988, and beginning on that same year, he was one of the original members of the American Hemp Council for four years with Chris Conrad and Jack Herer. Mr. Calkin is the author of “Starting Your Own Medical Marijuana Delivery Service: The Mobile Caregiver’s Handbook” which is a bestseller in the cannabis industry. He has been a consultant on the TV Show “Weeds” and he is the professor of “Delivery 102? at Oaksterdam University (Oakland, California), which uses his book for their curriculum. He is the founder and President of Cannabis Career Institute which opened in 2009, as well as Cannabis State University which began in 2010.
FINANCIALS AND CHART BELOW
CHECK OUT >>>> http://investorshub.advfn.com/boards/read_msg.aspx?message_id=104844025
cash: $1,042
current assets: $37 thousand
current liabilities: $3 million
quarterly net loss: $1.3 million
MONEY RUNNERS HAS SOMETHING HUGE COMING!!
YOU NEED TO BE A PART OF THIS RUNNER! SIGN UP BELOW
MORE NEWS @ http://moneyrunnersgroup.com/
Pleasant Kids mission is to educate and make the consumption of drinking high PH alkalized water fun!!!
The key in preventing dehydration, obesity, constipation and other health issues, is the appropriate consumption of pure water which assists with the improvement in mental and physical functions, optimum brain activity, healthy
sufficient body growth and contributes to provide more energy and a better life all around.
XUII finished the latest quarter with:
• $400 thousand cash
• $788 thousand total current assets
• $2.6 million total current liabilities
• ZERO revenues
• $1 million net loss
Check out >>>>>> http://investorshub.advfn.com/boards/read_msg.aspx?message_id=104602854
A TV commercial for it should begin airing in just a couple of days on a few major networks which should result in an influx of new users and hopefully funds will start flowing to the company.
XUII finished the latest quarter with:
• $400 thousand cash
• $788 thousand total current assets
• $2.6 million total current liabilities
• ZERO revenues
• $1 million net loss
Check out >>>>>> http://investorshub.advfn.com/boards/read_msg.aspx?message_id=104602854
A TV commercial for it should begin airing in just a couple of days on a few major networks which should result in an influx of new users and hopefully funds will start flowing to the company.